- Home
- COLL
as 07-26-2024 4:00pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 1.0B | IPO Year: | 2015 |
| Target Price: | $40.00 | AVG Volume (30 days): | 316.3K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.95 - $40.95 | Next Earning Date: | 08-08-2024 |
| Revenue: | $566,923,000 | Revenue Growth: | 8.00% |
| Revenue Growth (this year): | 5.04% | Revenue Growth (next year): | 2.55% |
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Jun 3 '24 | Sell | $32.55 | 24,300 | $790,926.12 | 140,109 | SEC Form 4 |
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Jun 3 '24 | Sell | $33.22 | 700 | $23,254.00 | 139,409 | SEC Form 4 |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | May 28 '24 | Sell | $34.21 | 19,710 | $674,367.80 | 130,845 | SEC Form 4 |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | May 23 '24 | Sell | $33.82 | 51,209 | $1,732,093.22 | 138,918 | SEC Form 4 |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | May 23 '24 | Sell | $33.98 | 56,807 | $1,930,455.24 | 105,902 | SEC Form 4 |
| BOHLIN GAREN G | COLL | Director | May 14 '24 | Sell | $32.30 | 28,985 | $936,311.15 | 44,775 | SEC Form 4 |
| Smith Thomas B | COLL | EVP and Chief Medical Officer | Feb 29 '24 | Sell | $36.76 | 995 | $36,580.18 | 63,409 | SEC Form 4 |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Feb 26 '24 | Sell | $36.38 | 9,336 | $339,600.73 | 139,582 | SEC Form 4 |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Feb 26 '24 | Sell | $37.15 | 664 | $24,669.59 | 138,918 | SEC Form 4 |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Jan 16 '24 | Sell | $32.28 | 23,560 | $760,519.16 | 111,322 | SEC Form 4 |
| Ciaffoni Joseph | COLL | President and CEO | Dec 21 '23 | Sell | $30.38 | 4,357 | $132,376.55 | 275,000 | SEC Form 4 |
| Ciaffoni Joseph | COLL | President and CEO | Dec 18 '23 | Sell | $30.04 | 27,798 | $834,935.17 | 275,000 | SEC Form 4 |
| Ciaffoni Joseph | COLL | President and CEO | Dec 18 '23 | Sell | $30.03 | 14,516 | $435,941.61 | 275,000 | SEC Form 4 |
| Ciaffoni Joseph | COLL | President and CEO | Dec 18 '23 | Sell | $30.40 | 26,454 | $804,209.54 | 275,000 | SEC Form 4 |
Latest Collegium Pharmaceutical Inc. News
COLL Breaking Stock News: Dive into COLL Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
Argus Research
3 days ago
COLL: Raising target price to $35.00
Argus Research
10 days ago
COLL: Raising target price to $34.00
Argus Research
17 days ago
COLL: Lowering target price to $33.00
Simply Wall St.
a month ago
Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years
MT Newswires
a month ago
Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity
GlobeNewswire
a month ago
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
Insider Monkey
2 months ago
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies
Compare COLL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.